144 related articles for article (PubMed ID: 24693197)
1. Localization and Molecular Characterization of human Breast Cancer Initiating Cells from heterogeneous population of Breast Cancer Mesenchymal Stem cells by Immunofluorescence Microscopy.
Potdar P; Monteiro F
J Stem Cells Regen Med; 2012; 8(3):190-7. PubMed ID: 24693197
[TBL] [Abstract][Full Text] [Related]
2. Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival.
Schlotter CM; Tietze L; Vogt U; Heinsen CV; Hahn A
Horm Mol Biol Clin Investig; 2017 Sep; 32(2):. PubMed ID: 28937963
[TBL] [Abstract][Full Text] [Related]
3. Dual-Receptor-Targeted (DRT) Radiation Nanomedicine Labeled with
Yook S; Cai Z; Jeong JJ; Lu Y; Winnik MA; Pignol JP; Reilly RM
Mol Pharm; 2020 Apr; 17(4):1226-1236. PubMed ID: 32022567
[TBL] [Abstract][Full Text] [Related]
4. Use of multiple biomarkers for the localization and characterization of colon cancer stem cells by indirect immunocytochemistry.
Amsterdam A; Raanan C; Schreiber L; Freyhan O; Fabrikant Y; Melzer E
Int J Oncol; 2012 Jul; 41(1):285-91. PubMed ID: 22504585
[TBL] [Abstract][Full Text] [Related]
5. Targeted imaging and inhibition of triple-negative breast cancer metastases by a PDGFRβ aptamer.
Camorani S; Hill BS; Collina F; Gargiulo S; Napolitano M; Cantile M; Di Bonito M; Botti G; Fedele M; Zannetti A; Cerchia L
Theranostics; 2018; 8(18):5178-5199. PubMed ID: 30429893
[TBL] [Abstract][Full Text] [Related]
6. Significance of heterogeneous Twist2 expression in human breast cancers.
Mao Y; Zhang N; Xu J; Ding Z; Zong R; Liu Z
PLoS One; 2012; 7(10):e48178. PubMed ID: 23133563
[TBL] [Abstract][Full Text] [Related]
7. A comparison of non-biologically active truncated EGF (EGFt) and full-length hEGF for delivery of Auger electron-emitting 111In to EGFR-positive breast cancer cells and tumor xenografts in athymic mice.
Panosa C; Fonge H; Ferrer-Batallé M; Menéndez JA; Massaguer A; De Llorens R; Reilly RM
Nucl Med Biol; 2015 Dec; 42(12):931-8. PubMed ID: 26385534
[TBL] [Abstract][Full Text] [Related]
8. A Targetable EGFR-Dependent Tumor-Initiating Program in Breast Cancer.
Savage P; Blanchet-Cohen A; Revil T; Badescu D; Saleh SMI; Wang YC; Zuo D; Liu L; Bertos NR; Munoz-Ramos V; Basik M; Petrecca K; Asselah J; Meterissian S; Guiot MC; Omeroglu A; Kleinman CL; Park M; Ragoussis J
Cell Rep; 2017 Oct; 21(5):1140-1149. PubMed ID: 29091754
[TBL] [Abstract][Full Text] [Related]
9. RB1 and p53 at the crossroad of EMT and triple-negative breast cancer.
Jiang Z; Jones R; Liu JC; Deng T; Robinson T; Chung PE; Wang S; Herschkowitz JI; Egan SE; Perou CM; Zacksenhaus E
Cell Cycle; 2011 May; 10(10):1563-70. PubMed ID: 21502814
[TBL] [Abstract][Full Text] [Related]
10. Inhibiting epidermal growth factor receptor signalling potentiates mesenchymal-epithelial transition of breast cancer stem cells and their responsiveness to anticancer drugs.
Manupati K; Dhoke NR; Debnath T; Yeeravalli R; Guguloth K; Saeidpour S; De UC; Debnath S; Das A
FEBS J; 2017 Jun; 284(12):1830-1854. PubMed ID: 28398698
[TBL] [Abstract][Full Text] [Related]
11. Cytoplasmic levels of cFLIP determine a broad susceptibility of breast cancer stem/progenitor-like cells to TRAIL.
French R; Hayward O; Jones S; Yang W; Clarkson R
Mol Cancer; 2015 Dec; 14():209. PubMed ID: 26667821
[TBL] [Abstract][Full Text] [Related]
12. Quantum dot-based molecular imaging of cancer cell growth using a clone formation assay.
Geng XF; Fang M; Liu SP; Li Y
Mol Med Rep; 2016 Oct; 14(4):3007-12. PubMed ID: 27572664
[TBL] [Abstract][Full Text] [Related]
13. Tumor initiating cancer stem cells from human breast cancer cell lines.
Han JS; Crowe DL
Int J Oncol; 2009 May; 34(5):1449-53. PubMed ID: 19360358
[TBL] [Abstract][Full Text] [Related]
14. Functional heterogeneity within the CD44 high human breast cancer stem cell-like compartment reveals a gene signature predictive of distant metastasis.
Leth-Larsen R; Terp MG; Christensen AG; Elias D; Kühlwein T; Jensen ON; Petersen OW; Ditzel HJ
Mol Med; 2012 Sep; 18(1):1109-21. PubMed ID: 22692575
[TBL] [Abstract][Full Text] [Related]
15. Characterization of stem cell and cancer stem cell populations in ovary and ovarian tumors.
Parte SC; Batra SK; Kakar SS
J Ovarian Res; 2018 Aug; 11(1):69. PubMed ID: 30121075
[TBL] [Abstract][Full Text] [Related]
16. Bladder cancer initiating cells (BCICs) are among EMA-CD44v6+ subset: novel methods for isolating undetermined cancer stem (initiating) cells.
Yang YM; Chang JW
Cancer Invest; 2008 Aug; 26(7):725-33. PubMed ID: 18608209
[TBL] [Abstract][Full Text] [Related]
17. BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment.
Lang JY; Hsu JL; Meric-Bernstam F; Chang CJ; Wang Q; Bao Y; Yamaguchi H; Xie X; Woodward WA; Yu D; Hortobagyi GN; Hung MC
Cancer Cell; 2011 Sep; 20(3):341-56. PubMed ID: 21907925
[TBL] [Abstract][Full Text] [Related]
18. Impact of stromal cell components of tumor microenvironment on epithelial-mesenchymal transition in breast cancer cells.
Bezdenezhnykh N; Semesiuk N; Lykhova O; Zhylchuk V; Kudryavets Y
Exp Oncol; 2014 Jun; 36(2):72-8. PubMed ID: 24980759
[TBL] [Abstract][Full Text] [Related]
19. Radiation Nanomedicine for EGFR-Positive Breast Cancer: Panitumumab-Modified Gold Nanoparticles Complexed to the β-Particle-Emitter, (177)Lu.
Yook S; Cai Z; Lu Y; Winnik MA; Pignol JP; Reilly RM
Mol Pharm; 2015 Nov; 12(11):3963-72. PubMed ID: 26402157
[TBL] [Abstract][Full Text] [Related]
20. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
